Scott Schaefer
Head of Investor Relations
Replay available
Neuropace, Inc. (NPCE) Q4 2025 Earnings Call
Neuropace, Inc. (NASDAQ: NPCE) Q4 2025 earnings conference call, held 2026-03-03. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Joel Becker
Chief Executive Officer
Patrick Williams
Chief Financial Officer
Frank Ticanin
Analyst, Lake Street Capital Markets
Mike Kretke
Analyst, Learing Partners
Priya Secdeva
Analyst, UBS
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Neuropace, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:06.019 Good afternoon and welcome to NeuroPace fourth quarter 2025 conference call. 00:00:06.019 -- 00:00:09.344 As a reminder, this call is being recorded. 00:00:09.344 -- 00:00:14.050 I would now like to turn the call over to Scott Schaefer, head of investor relations 00:00:14.050 -- 00:00:18.233 at NeuroPace for a few introductory comments. 00:00:20.599 -- 00:00:26.307 Thank you, operator, and welcome to NeuroPace's fourth quarter and full year 2025 earnings 00:00:26.307 -- 00:00:31.681 conference call. Our agenda begins with Joel Becker, Narrow Paces Chief Executive 00:00:31.681 -- 00:00:36.686 Officer, who will summarize our recent performance and strategic progress, followed 00:00:36.686 -- 00:00:41.250 by a detailed financial review and outlook from Patrick Williams, our Chief Financial 00:00:41.250 -- 00:00:47.013 Officer. Following our prepared remarks, we will open the call for questions. 00:00:47.135 -- 00:00:52.080 Before we begin, I would like to remind you that certain statements made on today's call 00:00:52.080 -- 00:00:57.044 may constitute forward-looking statements within the meaning of federal securities laws. 00:00:57.044 -- 00:01:01.641 These statements include, among others, comments regarding our financial outlook for 00:01:01.641 -- 00:01:03.143 2026 00:01:03.143 -- 00:01:05.526 and the first quarter of 2026, 00:01:05.526 -- 00:01:10.712 our commercial strategy, clinical and product development initiatives, regulatory 00:01:10.712 -- 00:01:16.099 matters including our IGE PMA supplement, and our expectations regarding operating 00:01:16.099 -- 00:01:18.981 performance and profitability. 00:01:19.163 -- 00:01:23.609 Forward-looking statements are based on management's current expectations and assumptions 00:01:23.6...